Brookstone Capital Management buys $4,040,931 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Brookstone Capital Management scooped up 8,929 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 68,735 shares of Merck & Co. which is valued at $4,040,931.Merck & Co. makes up approximately 0.52% of Brookstone Capital Management’s portfolio.

Other Hedge Funds, Including , Berkshire Asset Managementpa reduced its stake in MRK by selling 9,751 shares or 5.96% in the most recent quarter. The Hedge Fund company now holds 153,861 shares of MRK which is valued at $9,045,488. Merck & Co. makes up approx 1.34% of Berkshire Asset Managementpa’s portfolio.Hengehold Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 17 additional shares and now holds a total of 29,403 shares of Merck & Co. which is valued at $1,728,602. Merck & Co. makes up approx 0.55% of Hengehold Capital Management’s portfolio.Gateway Investment Advisers boosted its stake in MRK in the latest quarter, The investment management firm added 215,331 additional shares and now holds a total of 2,102,000 shares of Merck & Co. which is valued at $125,174,100. Merck & Co. makes up approx 1.05% of Gateway Investment Advisers’s portfolio.Benjamin F. Edwards Company reduced its stake in MRK by selling 168 shares or 1.07% in the most recent quarter. The Hedge Fund company now holds 15,588 shares of MRK which is valued at $928,265. Merck & Co. makes up approx 0.18% of Benjamin F. Edwards Company’s portfolio.Stillwater Investment Management boosted its stake in MRK in the latest quarter, The investment management firm added 46 additional shares and now holds a total of 5,603 shares of Merck & Co. which is valued at $332,538. Merck & Co. makes up approx 0.19% of Stillwater Investment Management’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.